B细胞导向疗法：应靶向哪些B细胞以及如何靶向？ - Suppr

Suppr

超能文献

B-cell-directed therapy: which B cells should be targeted and how?

作者信息

Yamamura Takashi, Miyake Sachiko

出版信息

Immunotherapy. 2012 May;4(5):455-7. doi: 10.2217/imt.12.35.

DOI:10.2217/imt.12.35

PMID:22642324

Abstract

摘要

相似文献

B-cell-directed therapy: which B cells should be targeted and how?

Immunotherapy. 2012 May;4(5):455-7. doi: 10.2217/imt.12.35.

Individualized rituximab treatment for neuromyelitis Optica spectrum disorders.

JAMA Neurol. 2013 Sep 1;70(9):1103-4. doi: 10.1001/jamaneurol.2013.3583.

Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum.

Mult Scler. 2013 Oct;19(11):1544-7. doi: 10.1177/1352458513498125. Epub 2013 Jul 25.

Inebilizumab-cdon.

Am J Health Syst Pharm. 2020 Oct 30;77(22):1812-1814. doi: 10.1093/ajhp/zxaa277.

[Topics of neuromyelitis optica].

Nihon Rinsho Meneki Gakkai Kaishi. 2014;37(6):468-74. doi: 10.2177/jsci.37.468.

Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels.

J Clin Neurosci. 2011 Jul;18(7):997-8. doi: 10.1016/j.jocn.2010.12.011. Epub 2011 May 11.

A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.

JAMA Neurol. 2013 Sep 1;70(9):1110-7. doi: 10.1001/jamaneurol.2013.3071.

Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy.

JAMA Neurol. 2013 Mar 1;70(3):394-7. doi: 10.1001/jamaneurol.2013.1246.

Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success.

Mult Scler. 2012 Jul;18(7):1022-6. doi: 10.1177/1352458511432896. Epub 2012 Jan 19.

CD19 mRNA quantification improves rituximab treatment-to-target approach: a proof of concept study.

J Neuroimmunol. 2014 Dec 15;277(1-2):127-33. doi: 10.1016/j.jneuroim.2014.09.008. Epub 2014 Sep 20.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

B-cell-directed therapy: which B cells should be targeted and how?

作者信息

Yamamura Takashi, Miyake Sachiko

出版信息

Immunotherapy. 2012 May;4(5):455-7. doi: 10.2217/imt.12.35.

DOI:10.2217/imt.12.35

PMID:22642324

Abstract

摘要

相似文献

B-cell-directed therapy: which B cells should be targeted and how?

Immunotherapy. 2012 May;4(5):455-7. doi: 10.2217/imt.12.35.

Individualized rituximab treatment for neuromyelitis Optica spectrum disorders.

JAMA Neurol. 2013 Sep 1;70(9):1103-4. doi: 10.1001/jamaneurol.2013.3583.

Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum.

Mult Scler. 2013 Oct;19(11):1544-7. doi: 10.1177/1352458513498125. Epub 2013 Jul 25.

Inebilizumab-cdon.

Am J Health Syst Pharm. 2020 Oct 30;77(22):1812-1814. doi: 10.1093/ajhp/zxaa277.

[Topics of neuromyelitis optica].

Nihon Rinsho Meneki Gakkai Kaishi. 2014;37(6):468-74. doi: 10.2177/jsci.37.468.

Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels.

J Clin Neurosci. 2011 Jul;18(7):997-8. doi: 10.1016/j.jocn.2010.12.011. Epub 2011 May 11.

A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.

JAMA Neurol. 2013 Sep 1;70(9):1110-7. doi: 10.1001/jamaneurol.2013.3071.

Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy.

JAMA Neurol. 2013 Mar 1;70(3):394-7. doi: 10.1001/jamaneurol.2013.1246.

Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success.

Mult Scler. 2012 Jul;18(7):1022-6. doi: 10.1177/1352458511432896. Epub 2012 Jan 19.

CD19 mRNA quantification improves rituximab treatment-to-target approach: a proof of concept study.

J Neuroimmunol. 2014 Dec 15;277(1-2):127-33. doi: 10.1016/j.jneuroim.2014.09.008. Epub 2014 Sep 20.